When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.jCr9XYTz.js ...

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...

The media queen also confessed that she was reluctant to take a GLP-1 drug because she felt it was “the easy way out.” That ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

GLP-1 drugs have also demonstrated potential in reducing risks of several substance use disorders such as those involving alcohol, tobacco, cannabis, opioids and stimulants. This may be due to the ...

News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side ...

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.